Editorial
Improvement in peripheral lung lesion evaluation and management requires ongoing advances in bronchoscopy
Translational Lung Cancer Research
2021;
10
(9)
:3694-3696
.
(30 September 2021)
PD-L1 expression in small cell lung cancer: should we designate it for assignment?
Translational Lung Cancer Research
2021;
10
(9)
:3697-3700
.
(30 September 2021)
Augmented fluoroscopy and cone beam CT-guided needle biopsy using a steerable guiding sheath: a promising approach for peripheral pulmonary lesions
Translational Lung Cancer Research
2021;
10
(9)
:3701-3704
.
(30 September 2021)
Cisplatin or carboplatin for advanced non-small cell lung cancer: does it really matter?
Translational Lung Cancer Research
2021;
10
(9)
:3705-3708
.
(30 September 2021)
Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(9)
:3709-3712
.
(30 September 2021)
Consensus
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(9)
:3713-3736
.
(30 September 2021)
Original Article
Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer
Translational Lung Cancer Research
2021;
10
(9)
:3737-3744
.
(30 September 2021)
Comparison of the efficiency of endobronchial ultrasound-guided transbronchial needle aspiration using a 22G needle versus 25G needle for the diagnosis of lymph node metastasis in patients with lung cancer: a prospective randomized, crossover study
Translational Lung Cancer Research
2021;
10
(9)
:3745-3758
.
(30 September 2021)
Electromagnetic bronchoscopy guided microwave ablation for early stage lung cancer presenting as ground glass nodule
Translational Lung Cancer Research
2021;
10
(9)
:3759-3770
.
(30 September 2021)
Prognostic and predictive impact of creatine kinase level in non-small cell lung cancer treated with tyrosine kinase inhibitors
Translational Lung Cancer Research
2021;
10
(9)
:3771-3781
.
(30 September 2021)
Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy
Translational Lung Cancer Research
2021;
10
(9)
:3782-3792
.
(30 September 2021)
Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial
Translational Lung Cancer Research
2021;
10
(9)
:3793-3806
.
(30 September 2021)
Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients
Translational Lung Cancer Research
2021;
10
(9)
:3807-3822
.
(30 September 2021)
Review Article
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review
Translational Lung Cancer Research
2021;
10
(9)
:3823-3839
.
(30 September 2021)
Case Report
A case report of primary signet ring cell carcinoma of the lung: imaging study and literature review
Translational Lung Cancer Research
2021;
10
(9)
:3840-3849
.
(30 September 2021)
Editorial Commentary
Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
Translational Lung Cancer Research
2021;
10
(9)
:3850-3854
.
(30 September 2021)
Thoracolaparoscopic carinal resection and reconstruction using pedicle omental flap
Translational Lung Cancer Research
2021;
10
(9)
:3855-3857
.
(30 September 2021)
Letter to the Editor
Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
Translational Lung Cancer Research
2021;
10
(9)
:3858-3860
.
(30 September 2021)
